RxDoctor Payments Data

Sarah Nielsen, APRN

Family · Wasilla, AKNPI 1366731218

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,230 and has fallen 59.0% since, to $504 in 2025. Among family clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,293in general payments, 2019–2025

Across 216 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$840
  • AbbVie$530
  • Astellas Pharma US Inc$366
  • GSK$316
  • Pfizer$205
  • Novo Nordisk$204
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,293 in reported general payments places this provider in the 95th percentile of 315 family providers in Alaska.

See all family providers in Alaska

Medicare billing

Part B allowed, 2024
$38,648
Medicare patients
117
Services billed
431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide15$15,561
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,477
Lisdexamfetamine Dimesylate11$3,148
SynthroidLevothyroxine Sodium11$853
Liothyronine Sodium22$845
Celecoxib15$770
Levothyroxine Sodium24$311
Omeprazole23$262
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$231
Duloxetine Hcl15$228
Rosuvastatin Calcium17$193
Lisinopril32$175
Tizanidine Hcl17$170
Metformin Hcl ErMetformin Hcl17$112
Gabapentin12$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$87$15,56115 claims
GSKTrelegy Ellipta$316$14,47718 claims
AbbVieSynthroid$530$85311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 315 family providers in Alaska.

Other family in Wasilla

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →